Securities code: 002755 securities abbreviation: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Announcement No.: 2022-007 Beijing Aosaikang Pharmaceutical Co.Ltd(002755)
Announcement on the general election of the board of supervisors of the company
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The term of office of the Fifth Board of supervisors of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (hereinafter referred to as “the company”) will expire on February 18, 2022. The general election shall be conducted in accordance with the company law, the stock listing rules of Shenzhen Stock Exchange, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange and other laws, regulations, normative documents and the relevant provisions of the articles of association.
The company held the 17th meeting of the 5th board of supervisors on January 21, 2022, deliberated and adopted the proposal on election of the board of supervisors and nomination of non employee representative supervisors of the 6th board of supervisors, and submitted it to the first extraordinary general meeting of shareholders in 2022 for deliberation.
The sixth board of supervisors of the company consists of three supervisors. The board of supervisors of the company nominated Mr. Chen Jing as the non employee representative supervisor of the sixth board of supervisors of the company (the candidate’s resume is attached).
Among the aforesaid candidates for non employee representative supervisors and employee representative supervisors elected by the employee congress, those who have served as directors or senior managers of the company in the last two years shall not exceed half of the total number of supervisors of the company; The number of supervisors nominated by a single shareholder shall not exceed half of the total number of supervisors of the company.
After being deliberated and approved by the general meeting of shareholders, the above candidates will form the sixth board of supervisors together with the employee representative supervisors elected by the employee congress of the company. The term of office of the supervisors of the sixth board of supervisors is three years, which will take effect from the date of adoption by the first extraordinary general meeting of shareholders of the company in 2022.
It is hereby announced.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) appendix of the board of supervisors on January 21, 2022
Resume of supervisor candidates of the 6th board of supervisors – non employee supervisors
1. Chen Jing, male, born in 1968, Chinese nationality, without permanent residency abroad. He has served as the chairman of the Beijing Aosaikang Pharmaceutical Co.Ltd(002755) board of supervisors since February 2019 and is now also the supervisor of Nanjing Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Investment Management Co., Ltd. Mr. Chen used to be an assistant to the general manager of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) pharmaceutical industry. Mr. Chen graduated from Nanjing University of Finance and economics in 2005.
Nanjing Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Investment Management Co., Ltd. is the controlling shareholder of the company, and Chen Jing is the supervisor of Nanjing Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Investment Management Co., Ltd.
In addition to the above, Chen Jing has no relationship with the controlling shareholder, actual controller, shareholders holding more than 5% of the company’s shares, directors, supervisors and senior managers.
Chen Jing does not directly hold shares of the company. Nanjing Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Investment Management Co., Ltd. holds 317470588 shares of the company, and Chen Jing holds 2.38% of the equity of Nanjing Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Investment Management Co., Ltd.
Chen Jing has not been punished by the CSRC and other relevant departments or the stock exchange in the past three years; There is no case where the judicial organ files a case for investigation due to suspected crime or the CSRC files a case for inspection due to suspected violation of laws and regulations, and there is no clear conclusion; There is no dishonest act, and he is not the person to be executed; It is not the subject of breach of faith responsibility or the object of breach of faith punishment; Meet the requirements of the company law and other relevant laws, regulations and provisions; There is no circumstance in which a person may not be nominated as a director.
